仅仅生物仿制品的不足利用并不预示着生物制品市场的破裂
Fariel LaMountain1, Molly T Beinfeld1, William Wong2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, United States.
Health affairs scholar
|July 29, 2024
概括
生物类似竞争可以降低生物药物价格,但原始人策略会影响市场份额. 与非独家优先策略相比,发行人独家优先覆盖维持了他们的市场地位.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 生物药物和生物类似药物
背景情况:
- 生物仿制药有望节省成本,并扩大对生物疗法的获取.
- 人们对市场上生物类似药的采用速度存在担忧.
研究的目的:
- 分析生物类似药与原始药物定价,覆盖范围和市场份额之间的联系.
- 评估不同覆盖策略对生物类药物吸收和原始人市场保留的影响.
主要方法:
- 检查了四个生物产品家族的案例研究.
- 将覆盖策略分为"唯一优先" (原始人优先) 和"非唯一优先" (两者都优先).
- 评估平均销售价格 (ASP) 降低和生物类似药物引入后的市场份额变化.
主要成果:
- 采用单一优先覆盖策略的发行人更有效地保留了表单偏好和市场份额.
- 无论策略如何,在生物类似药进入市场后,所有产品家族的市场加权ASP显著下降.
- 急剧的ASP减少 (≥50%) 是唯一首选策略的特征,而适度的减少发生在非唯一首选策略中.
结论:
- 覆盖策略在面对生物类似药的竞争中,显著影响发行商的市场份额和定价动态.
- 虽然生物类似药的引入推动了价格的降低,但仅市场份额和吸收可能无法完全捕捉到市场竞争和成本节约的程度.
相关概念视频
Bioequivalence: Overview
957
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
957
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Bioavailability: Overview
2.7K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.7K
Factors Influencing Drug Absorption: Presystemic Elimination
201
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
201
Factors Influencing Bioavailability: First-Pass Elimination
6.2K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.2K
Biopharmaceutics and Pharmacokinetics: Overview
1.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.9K


